For the 2 million Australians living with rare diseases, access to medicines can be inadequate. This report reassesses 2014 research by the McKell Institute, assessing the state of rare disease therapies in Australia.

This report focuses on six leading vaccine developers, assessing each company’s human rights policy, pricing structure, records on intellectual property, knowledge and technology sharing, allocation of available vaccine doses and transparency.

This audit is one of five performance audits conducted under phase one of the ANAO’s multi-year strategy that focuses on the effective, efficient, economical and ethical delivery of the Australian Government’s response to the COVID-19 pandemic, and the second of two performance audits focused on the NMS.

This guide, developed in partnership with the federal Department of Health, answers common questions about immunisation.

In October 2015, the NSW government enacted its pre-election commitment to waive the PBS co-payment for s100 HIV medications in NSW. This report describes respondents' experiences of the co-payment waiver.